neuroblastoma
Oncology · 2025–2025
1decision
1medicine
1carried consumer input
485individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eflornithine Post-maintenance treatment to prevent relapse in patients with high-risk neuroblastoma (HRNB) who are in remission after prior multiagent, multimodality… | Mar 2025 | Recommended with restriction | 485 individuals Oncology Group · Solid Tumour Group · Healthcare Australasia · Neuroblastoma Australia · Rare Cancers Australia · Medical Oncology Group |
Who spoke
Oncology Group · Solid Tumour Group · Healthcare Australasia · Neuroblastoma Australia · Rare Cancers Australia · Medical Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.